ATH-T 0.08 ARX-T 0.34 NVA-T 0.17 CGRE-T 0.3 RIT-T 0.16 ZRE-T 0.3
Daily Stock Opinions and Ratings
Stockchase Opinions

Glenn Paradis, BA, CFA Biomira BRA-T BUY ON WEAKNESS May 04, 2001

In phase 3 and has partnered with Merk.
Glenn Paradis, BA, CFAGlenn Paradis, BA, CFA
Unknown
Unlock Rating
$12.960

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Biomira(BRA-T)

May 18, 2001
Doesn't have top line growth. Some products in 3rd phase. Speculative.
John ZechnerJohn Zechner
Unknown
Unlock Rating
$11.080

Stock price when the opinion was issued

biotechnology pharmaceutical
WAIT

Biomira(BRA-T)

May 25, 2001
Taking a long time to get to market.
John ZechnerJohn Zechner
Unknown
Unlock Rating
$12.640

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Biomira(BRA-T)

Sep 19, 2001
Biotechs out of favour. Has broken $6.40. Next level is $3.90.
Brian Acker, CABrian Acker, CA
Unknown
Unlock Rating
$6.300

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Biomira(BRA-T)

Oct 31, 2001
Great product, but company has had problems.
Glenn Paradis, BA, CFAGlenn Paradis, BA, CFA
Unknown
Unlock Rating
$6.000

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Biomira(BRA-T)

Nov 14, 2001
Good long term investment, but prefers MDS.
Peter BriegerPeter Brieger
Unknown
Unlock Rating
$7.000

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY ON WEAKNESS

Biomira(BRA-T)

Dec 28, 2001
RISKY. No earnings. Treat as a trading stock between $5 and $7.
Brian Acker, CABrian Acker, CA
Unknown
Unlock Rating
$6.750

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Biomira(BRA-T)

Jan 16, 2002
Will take a while. Prefers Isotechnica,
Ray SteeleRay Steele
Unknown
Unlock Rating
$6.280

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Biomira(BRA-T)

Jan 16, 2003
Outlook is anybody's guess. No earnings.
Ross HealyRoss Healy
Unknown
Unlock Rating
$1.850

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Biomira(BRA-T)

Apr 23, 2004
The entire energy sector is an interesting play. There has been a shrinkage of capacity in the last several years.
Alison DeansAlison Deans
Owned
Unlock Rating
$67.580

Stock price when the opinion was issued

biotechnology pharmaceutical
SELL

Biomira(BRA-T)

Dec 03, 2004
Not a fan of biotech stocks. Difficult to read with all the little points of approval or non-approval. With the big spike, don't buy.
David ChapmanDavid Chapman
No
Unlock Rating
$3.880

Stock price when the opinion was issued

biotechnology pharmaceutical

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Latest Buy Signals

HWX-T 0.04$5.47
FRU-T 0.18$11.43
PD-T 0.68$58.75
BTE-T -0.02$2.24
VRN-T -0.04$8.01
Advertising

Today's Top Picks

ATH-T 0.08$4.6
ARX-T 0.34$25.75
NVA-T 0.17$11.57
CGRE-T 0.3$20.26
RIT-T 0.16$15.19

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

OXY-N -0.1$37.8
PNE-T 0.01125$0.6
CEU-T -0.01$6
PXT-T -0.07$11.03
TOU-T -0.03$60.71

Most Recent Experts

Eric Nuttall

Ninepoint Partners

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

David Burrows

Barometer Capital Management

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase Insights

5i Research

Advertising
Advertising
© Stockchase Inc.